Is Belite Bio Stock a Good Investment?
Belite Bio Investment Advice | BLTE |
- Examine Belite Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Belite Bio's leadership team and their track record. Good management can help Belite Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Belite Bio's business and its evolving consumer preferences.
- Compare Belite Bio's performance and market position to its competitors. Analyze how Belite Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Belite Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Belite Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Belite Bio ADR stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Belite Bio ADR is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Belite Bio Stock
Researching Belite Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 55.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.17. Belite Bio ADR had not issued any dividends in recent years.
To determine if Belite Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Belite Bio's research are outlined below:
| Net Loss for the year was (36.14 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Belite Bio ADR currently holds about 48.7 M in cash with (29.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.96. | |
| Roughly 55.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Belite Bios Earnings Call Cautious Optimism Amid Progress - TipRanks |
Belite Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Belite Bio ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Belite Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Belite Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Belite Bio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-08 | 2023-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2024-08-12 | 2024-06-30 | -0.26 | -0.31 | -0.05 | 19 | ||
2024-03-11 | 2023-12-31 | -0.3 | -0.25 | 0.05 | 16 | ||
2022-11-30 | 2022-09-30 | -0.175 | -0.11 | 0.065 | 37 | ||
2023-11-13 | 2023-09-30 | -0.32 | -0.4 | -0.08 | 25 | ||
2022-04-29 | 2022-03-31 | -0.28 | -0.4 | -0.12 | 42 | ||
2023-05-10 | 2023-03-31 | -0.2 | -0.33 | -0.13 | 65 | ||
2022-08-10 | 2022-06-30 | -0.23 | -0.08 | 0.15 | 65 |
Know Belite Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Belite Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Belite Bio ADR backward and forwards among themselves. Belite Bio's institutional investor refers to the entity that pools money to purchase Belite Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 2.5 K | Rhumbline Advisers | 2024-12-31 | 1.4 K | Gamma Investing Llc | 2024-12-31 | 1.3 K | Virtus Etf Advisers Llc | 2024-12-31 | 1.1 K | Advisors Preferred, Llc | 2024-12-31 | 798 | Mirae Asset Global Investments (korea) Co Ltd | 2024-12-31 | 357 | Sbi Securities Co Ltd | 2024-12-31 | 14.0 | Quantbot Technologies Llc | 2024-12-31 | 11.0 | Advisor Group Holdings, Inc. | 2024-12-31 | 7.0 | Armistice Capital, Llc | 2024-12-31 | 167.9 K | State Street Corp | 2024-12-31 | 20 K |
Belite Bio's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.19 B.Market Cap |
|
Belite Bio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.40) | (0.38) |
Determining Belite Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Belite Bio is a good buy. For example, gross profit margin measures Belite Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Belite Bio's profitability and make more informed investment decisions.
Please note, the presentation of Belite Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Belite Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Belite Bio's management manipulating its earnings.
Evaluate Belite Bio's management efficiency
Belite Bio ADR has return on total asset (ROA) of (0.2026) % which means that it has lost $0.2026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.306) %, meaning that it created substantial loss on money invested by shareholders. Belite Bio's management efficiency ratios could be used to measure how well Belite Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.42. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, Belite Bio's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 1.4 M, whereas Non Current Assets Total are forecasted to decline to about 2.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.06 | 3.21 | |
| Tangible Book Value Per Share | 2.95 | 3.10 | |
| Enterprise Value Over EBITDA | (32.24) | (33.85) | |
| Price Book Value Ratio | 12.11 | 12.71 | |
| Enterprise Value Multiple | (32.24) | (33.85) | |
| Price Fair Value | 12.11 | 12.71 | |
| Enterprise Value | 504.9 M | 291.2 M |
Understanding the operational decisions made by Belite Bio management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta (1.54) |
Basic technical analysis of Belite Stock
As of the 22nd of March, Belite Bio shows the Risk Adjusted Performance of 0.0519, downside deviation of 2.67, and Mean Deviation of 1.99. Belite Bio ADR technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Belite Bio ADR information ratio, as well as the relationship between the value at risk and expected short fall to decide if Belite Bio ADR is priced correctly, providing market reflects its regular price of 67.28 per share. Given that Belite Bio has jensen alpha of 0.1029, we suggest you to validate Belite Bio ADR's prevailing market performance to make sure the company can sustain itself at a future point.Belite Bio's Outstanding Corporate Bonds
Belite Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Belite Bio ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Belite bonds can be classified according to their maturity, which is the date when Belite Bio ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| BCECN 365 15 AUG 52 Corp BondUS0778FPAJ86 | View | |
| BCECN 32 15 FEB 52 Corp BondUS0778FPAH21 | View | |
| BCECN 215 15 FEB 32 Corp BondUS0778FPAG48 | View | |
| BCECN 365 17 MAR 51 Corp BondUS0778FPAF64 | View | |
| BELL CDA 4464 Corp BondUS0778FPAA77 | View | |
| BELL ATLANTIC PENNSYLVANIA INC Corp BondUS07786DAA46 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Understand Belite Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Belite Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0519 | |||
| Market Risk Adjusted Performance | (0.39) | |||
| Mean Deviation | 1.99 | |||
| Semi Deviation | 2.4 | |||
| Downside Deviation | 2.67 | |||
| Coefficient Of Variation | 1958.92 | |||
| Standard Deviation | 2.65 | |||
| Variance | 7.05 | |||
| Information Ratio | 0.0745 | |||
| Jensen Alpha | 0.1029 | |||
| Total Risk Alpha | 0.342 | |||
| Sortino Ratio | 0.0741 | |||
| Treynor Ratio | (0.40) | |||
| Maximum Drawdown | 12.46 | |||
| Value At Risk | (4.12) | |||
| Potential Upside | 4.97 | |||
| Downside Variance | 7.13 | |||
| Semi Variance | 5.77 | |||
| Expected Short fall | (2.00) | |||
| Skewness | 0.0693 | |||
| Kurtosis | 0.2578 |
| Risk Adjusted Performance | 0.0519 | |||
| Market Risk Adjusted Performance | (0.39) | |||
| Mean Deviation | 1.99 | |||
| Semi Deviation | 2.4 | |||
| Downside Deviation | 2.67 | |||
| Coefficient Of Variation | 1958.92 | |||
| Standard Deviation | 2.65 | |||
| Variance | 7.05 | |||
| Information Ratio | 0.0745 | |||
| Jensen Alpha | 0.1029 | |||
| Total Risk Alpha | 0.342 | |||
| Sortino Ratio | 0.0741 | |||
| Treynor Ratio | (0.40) | |||
| Maximum Drawdown | 12.46 | |||
| Value At Risk | (4.12) | |||
| Potential Upside | 4.97 | |||
| Downside Variance | 7.13 | |||
| Semi Variance | 5.77 | |||
| Expected Short fall | (2.00) | |||
| Skewness | 0.0693 | |||
| Kurtosis | 0.2578 |
Consider Belite Bio's intraday indicators
Belite Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Belite Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Belite Bio Corporate Filings
| 21st of March 2025 Other Reports | ViewVerify | |
6K | 18th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 17th of March 2025 Other Reports | ViewVerify | |
| 7th of February 2025 Other Reports | ViewVerify |
Belite Stock media impact
Far too much social signal, news, headlines, and media speculation about Belite Bio that are available to investors today. That information is available publicly through Belite media outlets and privately through word of mouth or via Belite internal channels. However, regardless of the origin, that massive amount of Belite data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Belite Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Belite Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Belite Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Belite Bio alpha.
Belite Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Belite Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Belite Bio Corporate Management
| ChingChen MSc | VP Operations | Profile | |
| YuHsin MBA | Chairman CEO | Profile | |
| CFA FRM | CFO Director | Profile | |
| MA MD | Chief Board | Profile | |
| Nathan Mata | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Belite Bio ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Belite Bio. If investors know Belite will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Belite Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Belite Bio ADR is measured differently than its book value, which is the value of Belite that is recorded on the company's balance sheet. Investors also form their own opinion of Belite Bio's value that differs from its market value or its book value, called intrinsic value, which is Belite Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Belite Bio's market value can be influenced by many factors that don't directly affect Belite Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Belite Bio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Belite Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Belite Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.